Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 36.23% | -21.00% | -100.49% | 20.04% | -98.20% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.24% | -37.58% | 168.41% | 275.76% | 153.85% |
| Change in Net Operating Assets | -136.24% | 2,678.57% | 1,198.98% | -387.17% | 3,199.00% |
| Cash from Operations | -1,621.51% | 33.09% | 3.38% | -40.90% | 89.51% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -81.24% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,784.62% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 24.20% | -- | -- |
| Cash from Financing | 2,972.22% | -- | -85.13% | -- | -99.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,486.23% | 289.23% | -302.57% | 187.37% | -108.65% |